Subscribe to Newsletter


Reset Filter
You have a filtered search result

271 search results for ‘*’

Manufacture Advanced Medicine

Stem Cells: The Next (Re)generation

| Rob Coker | 4 min read

CellProthera is demonstrating the safety and efficacy of a cell therapy approach to regenerating tissue following myocardial infarction

Discovery & Development Clinical Trials

Digitally Decentralized by Design

| Rob Coker | 3 min read

Through a partnership with software developer Medable, Syneos Health aims to decentralize and personalize clinical trials.

Discovery & Development Clinical Trials

The World’s Most Studied Disease

| Rob Coker | 5 min read

Breast cancer was the most researched disease in 2022. Phesi CEO Gen Li discusses what helps and what hinders the breast cancer research process.

Business & Regulation Profession

No One Left Behind

| Stephanie Sutton | 10 min read

We speak with Eric Dube, CEO of Travere Therapeutics, about his career and thoughts on leadership.

Business & Regulation Profession

Hybrid Theory

| Angus Stewart | 8 min read

Industry experience needn’t always come post-academia – other options are available, as we learned in our chat with this Northern Irish PhD candidate

Manufacture Advanced Medicine

A New Era in Healthcare

| Rob Coker | 3 min read

What are the societal impacts of rapid advances in the life science sector?

Manufacture Advanced Medicine

Titan on the Horizon

| Angus Stewart | 6 min read

Can digital tools help cell and gene therapy evolve?

Discovery & Development Drug Discovery

The Changing of The Season

| Rob Coker | 3 min read

Ulrike Gnad-Vogt talks us through CureVac’s efforts to target seasonal influenza

Discovery & Development Drug Discovery

Flu Season: March of the mAbs

| Rob Coker | 3 min read

As the world continues to take on the post-COVID flu epidemic, we ask RQ Bio CEO Hugo Fry what part monoclonal antibodies play in new flu treatments

Discovery & Development Drug Discovery

Getting Creative with Rare Diseases

| Rob Coker | 9 min read

Gene Sullivan, Chief Product Strategy Officer at Insmed, explores how new thinking could improve the research process for rare disease treatments

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine